RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

11/17/22 – RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Sleep Apnea

November 17, 2022

11/10/22 – RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4

November 10, 2022

11/7/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th Meridian Drug Discovery Summit

November 8, 2022

WATCH: RespireRx Interim CEO Arnold Lippa Presents Data at 2022 GRI Virtual Conference

WATCH: RespireRx Interim CEO Arnold Lippa Discusses Provisional Patent Application for a Novel Lipid-Based Formulation Technology (LFT)